Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 16, 2021

SELL
$10.24 - $20.87 $21.7 Million - $44.3 Million
-2,120,653 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$16.02 - $18.46 $34 Million - $39.1 Million
2,120,653 New
2,120,653 $39.1 Million

Others Institutions Holding ATHA

About Athira Pharma, Inc.


  • Ticker ATHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,817,700
  • Market Cap $23.4M
  • Description
  • Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...
More about ATHA
Track This Portfolio

Track Viking Global Investors LP Portfolio

Follow Viking Global Investors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Viking Global Investors LP, based on Form 13F filings with the SEC.

News

Stay updated on Viking Global Investors LP with notifications on news.